Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models

Tontanai Numbenjapon, Jianyi Wang, David Colcher, Thomas Schluep, Mark E. Davis, Julienne Duringer, Leo Kretzner, Yun Yen, Stephen J. Forman, Andrew Raubitschek

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated. Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice. Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.

Original languageEnglish
Pages (from-to)4365-4373
Number of pages9
JournalClinical Cancer Research
Volume15
Issue number13
DOIs
Publication statusPublished - Jul 1 2009
Externally publishedYes

Fingerprint

irinotecan
Camptothecin
Heterografts
Lymphoma
Polymers
Type I DNA Topoisomerase
Cell Line
Clinical Trials, Phase I
Maximum Tolerated Dose
Water
Poisons
IT-101

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Numbenjapon, T., Wang, J., Colcher, D., Schluep, T., Davis, M. E., Duringer, J., ... Raubitschek, A. (2009). Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clinical Cancer Research, 15(13), 4365-4373. https://doi.org/10.1158/1078-0432.CCR-08-2619

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. / Numbenjapon, Tontanai; Wang, Jianyi; Colcher, David; Schluep, Thomas; Davis, Mark E.; Duringer, Julienne; Kretzner, Leo; Yen, Yun; Forman, Stephen J.; Raubitschek, Andrew.

In: Clinical Cancer Research, Vol. 15, No. 13, 01.07.2009, p. 4365-4373.

Research output: Contribution to journalArticle

Numbenjapon, T, Wang, J, Colcher, D, Schluep, T, Davis, ME, Duringer, J, Kretzner, L, Yen, Y, Forman, SJ & Raubitschek, A 2009, 'Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models', Clinical Cancer Research, vol. 15, no. 13, pp. 4365-4373. https://doi.org/10.1158/1078-0432.CCR-08-2619
Numbenjapon, Tontanai ; Wang, Jianyi ; Colcher, David ; Schluep, Thomas ; Davis, Mark E. ; Duringer, Julienne ; Kretzner, Leo ; Yen, Yun ; Forman, Stephen J. ; Raubitschek, Andrew. / Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. In: Clinical Cancer Research. 2009 ; Vol. 15, No. 13. pp. 4365-4373.
@article{ed5f8ffdaf974d4a8f3dfb1c3ccc48d8,
title = "Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models",
abstract = "Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated. Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice. Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.",
author = "Tontanai Numbenjapon and Jianyi Wang and David Colcher and Thomas Schluep and Davis, {Mark E.} and Julienne Duringer and Leo Kretzner and Yun Yen and Forman, {Stephen J.} and Andrew Raubitschek",
year = "2009",
month = "7",
day = "1",
doi = "10.1158/1078-0432.CCR-08-2619",
language = "English",
volume = "15",
pages = "4365--4373",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models

AU - Numbenjapon, Tontanai

AU - Wang, Jianyi

AU - Colcher, David

AU - Schluep, Thomas

AU - Davis, Mark E.

AU - Duringer, Julienne

AU - Kretzner, Leo

AU - Yen, Yun

AU - Forman, Stephen J.

AU - Raubitschek, Andrew

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated. Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice. Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.

AB - Purpose: Camptothecin (CPT) has potent broad-spectrum antitumor activity by inhibiting type I DNA topoisomerase (DNA topo I). It has not been used clinically because it is water-insoluble and highly toxic. As a result, irinotecan (CPT-11), a water-soluble analogue of CPT, has been developed and used as salvage chemotherapy in patients with relapsed/refractory lymphoma, but with only modest activity. Recently, we have developed a cyclodextrin-based polymer conjugate of 20-(S)-CPT (IT-101). In this study, we evaluated the preclinical antilymphoma efficacy of IT-101 as compared with CPT-11. Experimental Design: We determined an in vitro cytotoxicity of IT-101, CPT-11, and their metabolites against multiple human lymphoma cell lines. In human lymphoma xenografts, the pharmacokinetics, inhibitions of tumor DNA topo I catalytic activity, and antilymphoma activities of these compounds were evaluated. Results: IT-101 and CPT had very high in vitro cytotoxicity against all lymphoma cell lines tested. As compared with CPT-11 and SN-38, IT-101 and CPT had longer release kinetics and significantly inhibit higher tumor DNA topo I catalytic activities. Furthermore, IT-101 showed significantly prolonged the survival of animals bearing s.c. and disseminated human xenografts when compared with CPT-11 at its maximum tolerated dose in mice. Conclusions: The promising present results provide the basis for a phase I clinical trial in patients with relapsed/refractory lymphoma.

UR - http://www.scopus.com/inward/record.url?scp=67650359893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650359893&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-08-2619

DO - 10.1158/1078-0432.CCR-08-2619

M3 - Article

C2 - 19549776

AN - SCOPUS:67650359893

VL - 15

SP - 4365

EP - 4373

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 13

ER -